# A Study to Determine the Safety and Efficacy of NT-501 in Macular Telangiectasia Type 2 - Protocol A

> **NCT03316300** · PHASE3 · COMPLETED · sponsor: **Neurotech Pharmaceuticals** · enrollment: 120 (actual)

## Conditions studied

- Macular Telangiectasia Type 2 (MacTel)

## Interventions

- **COMBINATION_PRODUCT:** NT-501
- **PROCEDURE:** Sham Procedure

## Key facts

- **NCT ID:** NCT03316300
- **Lead sponsor:** Neurotech Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2017-11-24
- **Primary completion:** 2022-08-31
- **Final completion:** 2022-09-23
- **Target enrollment:** 120 (ACTUAL)
- **Last updated:** 2024-09-24

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03316300

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03316300, "A Study to Determine the Safety and Efficacy of NT-501 in Macular Telangiectasia Type 2 - Protocol A". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT03316300. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*